Biomarin Pharmaceutical Incis A Global Biotechnology Company Based In San Rafaelcaliforniafounded In March 1997It Specializes In Developing And Commercializing Therapies For Rare Genetic Diseaseswith A Workforce Of 3 401 Employees And Reported Revenue Of $2 419 Billion In 2023Biomarin Has Established A Strong Presence In The Rare Disease Therapeutics Market The Company Focuses On Enzyme Replacement Therapies And Genetic Medicine Innovationtargeting Conditions With Significant Unmet Medical Needsits Key Products Include Aldurazymeafor Mucopolysaccharidosis Type Inaglazymeafor Mps Vipalynziqafor Phenylketonuriaand Roctavianafor Severe Hemophilia Aamong Othersbiomarin Also Maintains A Robust Pipeline Aimed At Conditions Like Duchenne Muscular Dystrophy And Emphasizes Gene Therapy And Precision Medicine In Its Research And Development Effortswith Manufacturing Facilities In California And Irelandbiomarin Ensures A Resilient Global Supply Chain To Support Its Operations
